Tissue distribution of terbinafine in rats.

Terbinafine is an allylamine antifungal agent that is highly lipophilic and keratophilic. The aim of this study was to investigate terbinafine distribution in peripheral and visceral tissues after intravenous administration to rats. Terbinafine, 6 mg/kg, was administered to 33 male Sprague-Dawley rats via a jugular vein cannula over 30 s. Groups of 3 rats were sacrificed at each of 11 time points (up to 24 h), and plasma and tissues were dissected, sampled, and analyzed by high-performance liquid chromatography. Terbinafine plasma concentrations declined in a triexponential fashion, with an estimated elimination half-life of 10 h. The estimated clearance of terbinafine in rats was 2 L/h/kg and the volume of distribution at steady state was 6 L/kg. The tissue-to-plasma partition coefficient (K(p)) of terbinafine for different tissues was calculated using the ratio of the area under the curve of concentration-time for tissues (AUC(tissue)) to that for plasma (AUC(plasma)), by parametric and semiparametric approaches. There was good agreement between K(p) estimates determined by different approaches. The preferential distribution of terbinafine to adipose and skin (K(p) = 49 and 45, respectively) was consistent with the lipophilicity of the drug. Uptake of terbinafine into brain (K(p) = 1.3) and muscle (K(p) = 1.0) was significantly lower. In conclusion, terbinafine displays extensive uptake to peripheral tissues, which contributes to the long elimination half-life of this drug.

[1]  K. Kwon,et al.  Physiological pharmacokinetic model for the distribution and elimination of tenoxicam , 1987 .

[2]  N. Ryder.  Specific inhibition of fungal sterol biosynthesis by SF 86-327, a new allylamine antimycotic agent , 1985, Antimicrobial Agents and Chemotherapy.

[3]  R. Youle,et al.  Pharmacokinetic analysis of immunotoxin uptake in solid tumors: role of plasma kinetics, capillary permeability, and binding. , 1990, Cancer research.

[4]  P. Nussbaumer,et al.  Synthesis and structure-activity relationships of side-chain-substituted analogs of the allylamine antimycotic terbinafine lacking the central amino function. , 1995, Journal of medicinal chemistry.

[5]  M. Delp,et al.  Physiological Parameter Values for Physiologically Based Pharmacokinetic Models , 1997, Toxicology and industrial health.

[6]  G. Petrányi,et al.  Antifungal activity of the allylamine derivative terbinafine in vitro , 1987, Antimicrobial Agents and Chemotherapy.

[7]  M. Zagula,et al.  Pilot study of terbinafine in children suffering from tinea capitis: evaluation of efficacy, safety and pharmacokinetics , 1995, The British journal of dermatology.

[8]  F Mentré,et al.  Population kinetics and conditional assessment of the optimal dosage regimen using the P-PHARM software package. , 1994, Anticancer research.

[9]  T. Jones,et al.  Terbinafine levels in serum, stratum corneum, dermis-epidermis (without stratum corneum), hair, sebum and eccrine sweat. , 1991, Acta dermato-venereologica.

[10]  J. Kovarik,et al.  Multiple-dose pharmacokinetics and distribution in tissue of terbinafine and metabolites , 1995, Antimicrobial agents and chemotherapy.

[11]  P V Pedersen,et al.  Novel deconvolution method for linear pharmacokinetic systems with polyexponential impulse response. , 1980, Journal of pharmaceutical sciences.

[12]  M. Nefzger,et al.  Major biotransformation routes of some allylamine antimycotics , 1987 .

[13]  J. Faergemann,et al.  Elimination Kinetics of Terbinafine from Human Plasma and Tissues following Multiple-Dose Administration, and Comparison with 3 Main Metabolites , 1994 .

[14]  L. Millérioux,et al.  Levels of terbinafine in plasma, stratum corneum, dermis–epidermis (without stratum corneum), sebum, hair and nails during and after 250 mg terbinafine orally once daily for 7 and 14 days , 1994, Clinical and experimental dermatology.

[15]  N. Ryder.  Mechanism of action of the allylamine antimycotics , 1987 .

[16]  L. Millérioux,et al.  Levels of terbinafine in plasma, stratum corneum, dermis-epidermis (without stratum corneum), sebum, hair and nails during and after 250 mg terbinafine orally once per day for four weeks. , 1993, Acta dermato-venereologica.

[17]  T. Hunt,et al.  Safe coadministration of terbinafine and terfenadine: A placebo‐controlled crossover study of pharmacokinetic and pharmacodynamic interactions in healthy volunteers , 1996, Clinical pharmacology and therapeutics.

[18]  Y. Clayton.  In vitro activity of terbinafine , 1989, Clinical and experimental dermatology.

[19]  A. McLachlan,et al.  Determination of terbinafine in tissues. , 2000, Biomedical chromatography : BMC.

[20]  N. Ryder.  Effect of allylamine antimycotic agents on fungal sterol biosynthesis measured by sterol side-chain methylation. , 1985, Journal of General Microbiology.

[21]  J. Jensen,et al.  Clinical pharmacokinetics of terbinafine (Lamisil) , 1989, Clinical and experimental dermatology.

[22]  T Iwatsubo,et al.  PREDICTION OF IN VIVO DRUG DISPOSITION FROM IN VITRO DATA BASED ON PHYSIOLOGICAL PHARMACOKINETICS , 1996, Biopharmaceutics & drug disposition.

[23]  A. Finlay.  Pharmacokinetics of terbinafine in the nail. , 1992, The British journal of dermatology.

[24]  Malcolm Rowland,et al.  Clinical pharmacokinetics : concepts and applications , 1989 .

[25]  G. Petrányi,et al.  Activity of terbinafine in experimental fungal infections of laboratory animals , 1987, Antimicrobial Agents and Chemotherapy.

[26]  Y. Clayton.  Relevance of broad‐spectrum and fungicidal activity of antifungals in the treatment of dermatomycoses , 1994, The British journal of dermatology.

[27]  J. Kovarik,et al.  Dose‐proportional pharmacokinetics of terbinafine and its N‐demethylated metabolite in healthy volunteers , 1992, The British journal of dermatology.